فهرست نشریات علمی دسترسی آزاد ایران

Background: Chronic kidney disease (CKD) is a worldwide health problem. But despite to new routes of dialysis, mortality and morbidity is high. One of the most common symptom of CKD is anemia, especially is more obvious in stages 3 and 4. Objectives: In this study, the effects of erythropoietin on renal function were assessed by measurement of serum creatinine level. Results: Mean of creatinine and 1/creatinine values in 4 stages including three-month before intervention, time to intervention, and the three months after the intervention and the six month after the intervention were 2.17 and 0.50; 2.45 and 0.45; 2.41 and 0.47; 2.30 and 0.49 respectively which were not statistically significant. Conclusion: The administration of recombinant human erythropoietin in stage 3 and 4 of chronic kidney disease, improves anemia with no impact on renal function.